Provided by Tiger Trade Technology Pte. Ltd.

MannKind

3.94
-0.2200-5.29%
Pre-market: 3.940.00000.00%04:10 EDT
Volume:5.19M
Turnover:20.94M
Market Cap:1.27B
PE:-28.14
High:4.36
Open:4.16
Low:3.92
Close:4.16
52wk High:6.51
52wk Low:2.23
Shares:321.54M
Float Shares:309.97M
Volume Ratio:1.74
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1400
EPS(LYR):0.0200
ROE:32.74%
ROA:0.79%
PB:-18.85
PE(LYR):197.00

Loading ...

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)

TIPRANKS
·
Aug 06

MannKind Q2 2026 Earnings: Revenue Rises 43% as Costs Drive a Net Loss

TradingKey
·
Aug 06

MannKind Corporation Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

MannKind reports Q2 EPS (6c), consensus 2c

TIPRANKS
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06

MannKind Q2 Adj. EPS $(0.01) Misses $(0.00) Estimate, Sales $109.374M Beat $108.915M Estimate

Benzinga Earnings
·
Aug 06

MannKind Q2 Net Income USD -19.032 Million

Reuters
·
Aug 06

MannKind Q2 Operating Income USD -350 Thousand

THOMSON REUTERS
·
Aug 06

MannKind Q2 Basic EPS USD -0.06

THOMSON REUTERS
·
Aug 06

MannKind Corp Expected to Post Breakeven Results a Share - Earnings Preview

Reuters
·
Aug 04

MannKind Posts Transcript of Nintedanib DPI Phase 1b Results Call

Reuters
·
Aug 01

MannKind Top-Line Data From Phase 1b INFLO-1 Study 'Positive,' Wedbush Says

MT Newswires Live
·
Jul 30

MannKind is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Teva Pharmaceutical (TEVA) and MannKind (MNKD)

TIPRANKS
·
Jul 30

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Humana (HUM)

TIPRANKS
·
Jul 30

MannKind price target raised to $14 from $11 at Wells Fargo

TIPRANKS
·
Jul 30

Earning Preview: MannKind Q2 revenue expected to rise about 39%, institutional views tilt positive

Earnings Agent
·
Jul 30

MannKind Says Phase 1b Study Shows Idiopathic Pulmonary Fibrosis Treatment Generally Safe, Well-Tolerated

MT Newswires Live
·
Jul 29

MannKind Corp - Nintedanib DPI Generally Safe and Well Tolerated in Phase 1B Ipf Study

THOMSON REUTERS
·
Jul 29

MannKind Reports Positive Phase 1B Inflo-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in Ipf

THOMSON REUTERS
·
Jul 29